Bristol-Myers Squibb CEO Giovanni Caforio defended his company's $74 billion bid for cancer drug maker Celgene in an interview with CNBC's Jim Cramer on Wednesday. The move is facing opposition from the Wellington Management, Bristol-Myers' largest stakeholder, and Starboard Value hedge funds. The acquisition, which will be voted on my shareholders next week, would add